To Study the Efficacy of FF/VI Combination in Adult Asthma Patients

Simple item page
dc.contributor.authorSarin, BCen_US
dc.contributor.authorGrover, Sen_US
dc.contributor.authorAulakh, JK.en_US
dc.date.accessioned2025-05-09T11:00:44Z
dc.date.available2025-05-09T11:00:44Z
dc.date.issued2024-12
dc.description.abstractBackground: Long-acting beta2-agonists (LABA) and inhaled corticosteroids require twice daily administration for effective treatment of bronchial asthma. This study aims to study the efficacy of fluticasone furoate/vilanterol (FF/VI) ICS/Ultra-LABA once-daily combination therapy in patients with bronchial asthma. Materials and methods: This prospective observational study included 120 spirometry-diagnosed patients of bronchial asthma who were given FF/VI combination therapy and underwent follow-up at 2, 4, and 8 weeks of therapy. Patients were assessed during the follow-up period for the efficacy of therapy based on spirometric values. Results: In the present study 61.7% were females and 38.3% were males. The commonest presenting symptom was cough present in 95% of patients followed by wheezing which was seen in 93.3% of patients and shortness of breath in 89.17% of patients. At 8 weeks of continuous therapy, only 5% of patients had a cough, 8.33% had wheezing and only 2.5% complained of shortness of breath. Forced expiratory volume (FEV) in one second (FEV1) at baseline, was 56.60 ± 1.26, and by the end of 8 weeks, it increased to 90.36 ± 11.38. Forced vital capacity (FVC) at baseline was 64.83 ± 12.63 and it increased to 91.8 ± 1035 at 8 weeks. Forced expiratory volume in one second (FEV1)/FVC at baseline was 63.31 ± 4.90 and it increased to 74.59 ± 3.19 at 8 weeks. Forced expiratory flow (FEF) 25–75% at baseline was 35.42 ± 14.74, and at 8 weeks of continuous therapy, it increased to 76.35 ± 8.85 and all these values were statistically significant (p < 0.05). The spirometric mean values were highly significant (p < 0.001) in between 2–4 weeks and 4–8 weeks. Conclusion: Therapeutic continuity of FF/VI combination therapy is significantly effective in improving both symptoms and spirometric values in bronchial asthma patients. The safety profile and improvements in lung function irrespective of dosing time (morning or evening) strongly emphasize strict adherence to continuous once-daily use of the inhaler FF/VI to fully reverse the condition.en_US
dc.identifier.affiliationsDepartment of Pulmonary Medicine, Sri Guru Ram Das Institute of Medical Sciences & Research, Amritsar, Punjab, Indiaen_US
dc.identifier.affiliationsDepartment of Pulmonary Medicine, Sri Guru Ram Das Institute of Medical Sciences & Research, Amritsar, Punjab, Indiaen_US
dc.identifier.affiliationsDepartment of Pulmonary Medicine, Sri Guru Ram Das Institute of Medical Sciences & Research, Amritsar, Punjab, Indiaen_US
dc.identifier.citationSarin BC, Grover S, Aulakh JK.. To Study the Efficacy of FF/VI Combination in Adult Asthma Patients . The Indian Journal of Chest Diseases and Allied Sciences. 2024 Dec; 66(4): 118-123en_US
dc.identifier.issn0377-9343
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/245831
dc.languageenen_US
dc.publisherJaypee Brothers Medical Publishers Pvt. Ltd.en_US
dc.relation.issuenumber4en_US
dc.relation.volume66en_US
dc.source.urihttps://doi.org/10.5005/jp-journals-11007-0137en_US
dc.subjectBronchial asthmaen_US
dc.subjectFluticasone furoateen_US
dc.subjectSpirometryen_US
dc.subjectVilanterolen_US
dc.titleTo Study the Efficacy of FF/VI Combination in Adult Asthma Patientsen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ijcdas2024v66n4p118.pdf
Size:
589.17 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Chest Diseases & Allied Sciences